Treatment of postmenopausal osteoporosis in women: A systematic review

Cadernos de Saude Publica

Volumn 24, Issue SUPPL.4, 2008, Pages

  Brandão, Cristina Mariano Ruas ^a   Lima, Marina Guimarães ^a   Da Silva, Anderson Lourenço ^a   Silva, Graziele Dias ^a   Guerra Jr , Augusto Afonso ^a   De Assis Acúrcio, Francisco ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52949104739     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/s0102-311x2008001600011     Document Type: Review

References (59)

1. Silva LK. Avaliação tecnológica em saúde: densitometria óssea e terapêuticas alternativas na osteoporose pós-menopausa. Cad Saúde Pública 2003; 19:987-1003.
2. Costa-Paiva L, Horovitz AP, Santos AO, Fonsechi-Carvasan GA, Pinto-Neto AM. Prevalência de osteoporose em mulheres na pós-menopausa e associação com fatores clínicos e reprodutivos. Rev Bras Ginecol Obstet 2003; 25:507-12.
3. Frazão P, Naveira M. Prevalência de osteoporose: uma revisão crítica. Rev Bras Epidemiol 2006; 9:206-14.
4. World Health Organization Scientific Group on the Prevention and Management of Osteoporosis. Prevention and management of osteoporosis. Geneva: World Health Organization; 2003. (Technical Report Series, 921).
5. Brasil. Portaria no. 2.577/GM, de 27 de outubro de 2006. Aprova o componente de medicamentos de dispensação excepcional. Diário Oficial da União 2006; 27 out.
6. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, et al. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modeling study. Health Technol Assess 2005; 9:1-193.
7. Ensrud KE, Black DM, Palermo L, Bauer DC, Barrett-Connor E, Quandt SA, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997; 157:2617-24.
8. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, et al. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study. J Bone Miner Metab 2004; 22:462-8.
9. Chestnut III CH, McClung MR, Ensrud KE. Alendronate treatment of posmenopausal women: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995; 99:144-52.
10. Luckey MM, Gilchrist N, Bone HG, Davie MW, De Villiers TJ, Wu M, et al. Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 2003; 101:711-21.
11. Sambrook PN, Geusens P, Ribot C, Solimano JA, Ferrer-Barriendos J, Gaines K, et al. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Intern Med 2004; 255:503-11.
12. Pols HAP, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Willkin TJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results the FOSIT study. Osteoporos Int 1999; 9: 461-8.
13. Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000; 85:720-6.
14. Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, et al. Once-weekly alendronate 70mg and raloxifene 60mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004; 11:405-15.
15. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71:103-11.
16. Ste-Marie LG, Sod E, Johnson T, Chines A. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. Calcif Tissue Int 2004; 75:469-76.
17. Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 1997;7:488-95.
18. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-52.
19. Hooper MJ, Ebeling PR, Roberts A P, Graham JJ, Nicholson GC, D'Emden M, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric 2005; 8:251-62.
20. Felsenberg D, Miller P, Armbrecht G, Wilson K, Schimmer RC, Papapoulos SE. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in post-menopausal women with osteoporosis. Bone 2005; 37:651-4.
21. Chesnut CH, Ettinger MP, Miller PD, Baylink DJ, Emkey R, Harris ST, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. Curr Med Res Opin 2004; 21: 391-401.
22. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral iban-dronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005; 20:1315-22.
23. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and toler-ability of once-monthly oral ibandronate in post-menopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006; 65:654-61.
24. Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, et al. Efficacy and safety of oral weekly ibandronate in the treatment of post-menopausal osteoporosis. J Clin Endocrinol Metab 2003; 88:4609-15.
25. Recker R, Stakkestad JA, Chesnut CH, Christiansen C, Skag A, Hoiseth A, et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in post-menopausal osteoporosis. Bone 2004; 34:890-9.
26. Adami S, Felsenberg D, Christiansen C, Robinson J, Lorenc RS, Mahoney P, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004; 34:881-9.
27. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, et al. Intravenous iban-dronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54:1838-46.
28. McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res 2004; 19:728-36.
29. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653-61.
30. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of post-menopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117:1-9.
31. Hodsman AB, Hanley DA, Ettinger M P, Bolognese MA, Fox J, Metcalfe AJ, et al. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88:5212-20.
32. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87:4528-35.
33. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109:267-76.
34. Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, et al. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial. Osteoporos Int 2003; 14:793-800.
35. Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, et al. The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial. Ann Intern Med 1998; 129:1-8.
36. Reid IR, Cundy T, Grey AB, Horne A, Clearwater J, Ames R, et al. Addition of monofluorophosphate to estrogen therapy in postmenopausal osteoporosis: a randomized controlled trial. J Clin Endo-crinol Metab 2007; 92:2446-52.
37. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350:459-68.
38. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, et al. Strontium ranelate: an increased bone quality leading to vertebral an-tifracture efficacy at all stages. J Clin Endocrinol Metab 2002; 87:2060-6.
39. Adachi JD. Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy. Can Fam Physician 1998;44:327-32.
40. Tsun EC, Heck AM. Intermittent dosing of alendro-nato. Ann Pharmacother 2001; 35:1471-5.
41. Adachi JD, Rizzoli R, Boonen S, Li Z, Meredith MP, Chesnut CH. Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. Aging Clin Exp Res 2005; 172:150-6.
42. Crandall C. Risedronate: a clinical review. Arch Intern Med 2001; 161:353-60.
43. Maricic M. New and emerging treatments for osteoporosis. Curr Opin Rheumatol 2007; 19:363-9.
44. Pyon EY. Once-monthly ibandronate for post-menopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006; 28:475-90.
45. Miller PD. Optimizing the management of post-menopausal osteoporosis with biphosphonates: the emerging role of intermittent therapy. Clin Ther 2005; 27:361-76.
46. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006; 28:151-73.
47. Eichner FS, Lloyd KB, Timpe EM. Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 2003; 37: 711-24.
48. Writing Group for the Women's Health Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-33.
49. Rozenfeld S. Terapia hormonal para a menopausa (TH): múltiplos interesses a considerar. Ciênc Saúde Coletiva 2007; 12:437-42.
50. Barret-Connor E, Wehren LE, Siris ES, Miller P, Chen Y, Abbot 3rd TA, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Ostoporosis Risk Assessment (NORA) study. Menopause 2003; 10:412-9.
51. van Staa TP, Cooper C, Barlow D, Leufkens HGM. Individualizing the risks and benefits of post-menopausal hormone therapy. Menopause 2008; 15:374-81.
52. Fadanelli ME, Bone HG. Combining bisphospho-nates with hormone therapy for postmenopausal osteoporosis. Treat Endocrinol 2004; 3:361-9.
53. Cranney A, Papaioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D. Parathyroid hormone for treatment of osteoporosis: a systematic review. CMAJ 2006; 175:52-9.
54. Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, et al. Parathyroid hormone and Teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26:688-703.
55. Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on β-endorphin levels in postmeno-pausal osteoporotic patients with back pain. Clin Rheumatol 2007; 26:44-9.
56. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R. Selective estrogen receptor modulators for post-menopausal osteoporosis: current state of development. Drugs Aging 2007; 24:361-79.
57. Vestergaard P, Jorgensen NR, Schwarz P, Mosekilde L. Effects of treatment with fluoride on bone mineral density and fracture risk: a meta-analysis. Os-teoporos Int 2008; 19:257-68.
58. O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2007. Oxford: Update Software.
59. Wasnisch RD, Miller PD. Antifracture efficacy of antireabsorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2007; 85:231-6.